~shared on behalf of the Health Antimicrobial Stewardship Program
Extended release formulations of nitrofurantoin 100 mg capsules (i.e. generics for MacrobidÒ) are currently not available. NS Health supply is low and access in the community is also limited. There are two manufacturers. PMS’s resolution date is January 2025; Auro’s is later in September however, this has already been subject to multiple delays.
As always, judicious use of antimicrobials for treatment of uncomplicated UTI is advised. If extended release nitrofurantoin is unavailable, the NS Health Antimicrobial Stewardship program preferentially suggests the following as alternatives:
- Nitrofurantoin (regular release) 50-100 mg QID OR
- Fosfomycin 3 g orally as one dose as alternatives to Macrobid
Nitrofurantoin and fosfomycin are preferred for uncomplicated UTIs over amoxicillin-clavulanate since both concentrate in the urine and have narrower spectrums of activity. Both are usually more active than cephalexin and trimethoprim-sulfamethoxazole for urinary pathogens.
Nova Scotia Pharmacare will be changing their exception status criteria to allow the use of fosfomycin as a first line agent for uncomplicated UTIs in the community.
Updates for this shortage will be posted in the Drug Shortages - Home (nshealth.ca) website.
If you have any questions or need help with antibiotic selection, please contact pharmacy or a member of the AMS team.
|